Aridis Pharmaceuticals
Aridis Pharmaceuticals develops novel therapies for infectious diseases, focusing on monoclonal antibodies from convalescent patients, with a pipeline addressing hospital-acquired infections, cystic fibrosis, and COVID-19.
Company Overview
Aridis Pharmaceuticals develops novel, differentiated therapies for infectious diseases. The company focuses on the discovery and development of monoclonal antibodies derived from convalescent patients who have recovered from infections. Their work involves advanced proprietary technology platforms like ⅄PEXTM and MabIgX® to facilitate rapid antibody discovery.
Monoclonal Antibody Pipeline
Aridis Pharmaceuticals' pipeline includes several monoclonal antibodies: AR-301 (Tosatoxumab), AR-320 (Suvratoxumab), AR-501 (Panaecin™), and AR-701. AR-301 targets S. aureus alpha-toxin and is currently in Phase 3 clinical trials for treating ventilator-associated pneumonia. AR-320 is designed as a pre-emptive treatment for S. aureus in mechanically ventilated ICU patients. AR-501, an inhalable gallium citrate formulation, is promising for antibiotic-resistant bacteria, while AR-701 targets envelope proteins of SARS-CoV-2.
Technological Platforms
Aridis Pharmaceuticals utilizes two proprietary technology platforms: ⅄PEXTM and MabIgX®. ⅄PEXTM enables rapid antibody discovery, providing a robust framework for identifying therapeutic antibodies. MabIgX® also enhances the antibody discovery process, allowing the company to efficiently develop targeted therapies for various infectious diseases.
Therapeutic Areas
Aridis Pharmaceuticals addresses various therapeutic areas, including hospital-acquired infections, cystic fibrosis, and COVID-19. Their development of monoclonal antibodies focuses on fighting severe infections in healthcare settings and improving outcomes for patients with serious respiratory conditions. The company is proactive in targeting pathogens that pose significant health risks, including antibiotic-resistant bacteria and emerging viruses like SARS-CoV-2.